Oct 16, 2024
PLYMOUTH MEETING, Pa. , Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024 , before the open of the U.S. financial markets.
Oct 15, 2024
Harmony Biosciences has announced the newest recipients of its Progress at the Heart and Patients at the Heart Awards programs, which provide funding support for community and nonprofit organizations working to develop innovative, patient-centric initiatives that help drive meaningful change for
Oct 01, 2024
BP1.15205 Data Indicates Potential Best-In-Class Orexin-2 Agonist Based on Highest Potency New Data Shows Clinically Meaningful Sustained Efficacy of Pitolisant in Patients with Idiopathic Hypersomnia in Long-Term Extension Study; On Track to Submit sNDA in Q4 2024 Preliminary Data Establish
Sep 26, 2024
Company leadership and key opinion leaders to share new data and provide late-stage pipeline updates PLYMOUTH MEETING, Pa. , Sept. 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at
Aug 21, 2024
PLYMOUTH MEETING, Pa. , Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Wells Fargo 2024 Healthcare Conference Location: Boston Fireside Chat:
Aug 06, 2024
WAKIX ® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program Advances Based on Pilot Pharmacokinetic ( PK) Data with PDUFA Date Expected in 2028 to Extend Pitolisant Franchise Beyond 2040 WAKIX Patent Upheld
